NEW YORK, April 15, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Amaya Inc. (“Amaya”) (NASDAQ:AYA) between June 8, 2015 and March 23, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Amaya securities between June 8, 2015 and March 23, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/amaya-inc.
The complaint alleges that the Company violated federal securities laws by failing to disclose that its CEO David Baazov was involved in insider trading. On March 23, 2016, Amaya issued a press release acknowledging that Canadian securities regulators have charged Baazov with insider trading. The allegations concern the communication of privileged information involve a “former financial advisor to Amaya.”
If you suffered a loss in Amaya you have until May 24, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/amaya-inc.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



